March 26, 2024

As­traZeneca’s rare dis­ease arm Alex­ion scored its fourth ap­proval for Ul­tomiris in a rare au­toim­mune dis­or­der af­ter Phase 3 da­ta showed there were ze­ro pa­tients with

BioN­Tech dis­closed on Mon­day that it re­ceived a “no­tice of de­fault” from the NIH over al­leged breach­es to a li­cense agree­ment re­lat­ed to its Pfiz­er-part­nered

Peo­ple liv­ing with se­vere asth­ma are lit­er­al­ly step­ping away from so­cial me­dia and in­to ac­tive out­door lives in As­traZeneca’s newest cam­paign for its asth­ma med­ica­tion

The Biden ad­min­is­tra­tion is en­list­ing AI de­vel­op­ers to help dis­cov­er ways to tack­le cy­ber and ran­somware at­tacks against health­care sys­tems, which have been on the

In Con­gress, in­flu­en­tial law­mak­ers see a Chi­nese gov­ern­ment threat to the US biotech sec­tor. In the com­pet­i­tive world of bio­phar­ma man­u­fac­tur­ing, com­pa­nies see an op­por­tu­ni­ty.

Plus, news about AriBio, Fer­rer, Verge Ge­nomics, Ther­at­e­ch­nolo­gies and BioX­cel Ther­a­peu­tics: Ax­some re­ports late-phase da­ta in nar­colep­sy: The biotech’s AXS-12 (re­box­e­tine) suc­ceed­ed in re­duc­ing cat­a­plexy

The FDA gave the green light to In­vivyd’s Pem­gar­da for Covid-19 pre­ven­tion in high-risk im­muno­com­pro­mised pa­tients, is­su­ing an emer­gency use au­tho­riza­tion on Fri­day for the

Ab­b­Vie is ac­quir­ing au­toim­mune start­up Lan­dos Bio­phar­ma, ac­cord­ing to a Mon­day an­nounce­ment, aim­ing to cap­i­tal­ize on an IBD drug that re­cent­ly en­tered Phase 2. The

Nu­va­tion Bio plans to buy An­Heart Ther­a­peu­tics in an all-stock deal, the can­cer drug de­vel­op­ers said Mon­day morn­ing, in a move that could turn Nu­va­tion